{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13.7","upperLimit":"28.0","value":"20.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"134"}],"units":"Participants"}],"description":"False Positive Rate at the patient level (FPRp) will be a major secondary efficacy endpoint and is defined as the percentage of women who underwent both normal light and fluorescent light (Intent-to-Image Set)","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients exposed to OTL38 and who were randomly assigned to undergo NIR fluorescent imaging (OTL38+imaging) and who:\n\n* Were evaluated under both normal light and NIR fluorescent light imaging\n* Had central pathology and histology confirmation for at least one FR+ ovarian cancer lesion detected under normal light or NIR fluorescent light imaging","id":"OG000","title":"Full Analysis Set"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"30 days","title":"Patient False Positive Rate","type":"SECONDARY","unitOfMeasure":"percentage of participants"}